ArticleProbiotics and antimicrobial proteins2026
Bifidobacterium animalis subsp. lactis GOLDGUT-BB69 Counteracts Diarrhea in Mice by Alleviating Inflammation, Enhancing Intestinal Barrier Functions, and Regulating Intestinal Microbiota.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In this study, we assessed the therapeutic effects of Bifidobacterium animalis subsp. lactis GOLDGUT-BB69 (BB69) on diarrhea in mice by monitoring diarrhea scores, intestinal histopathology, detecting cytokine and protein expression, and intestinal microbial composition and metabolism. The results showed that BB69 significantly reduced the disease symptoms of diarrhea in mice, attenuated the pathological features of the intestine, decrease the protein expression in the TLR4/NF-κB signaling pathway, reduced intestinal inflammation, lowered intestinal permeability, and significantly increased the expression of mucin and tight junction proteins (ZO-1, occludin), which repaired intestinal mucosal injuries and enhanced the intestinal barrier function. In addition, BB69 significantly reduced the gut dysbiosis of mice with diarrhea by increasing the abundance and diversity of intestinal microorganisms and the content of short-chain fatty acids (SCFAs). Our findings suggest that BB69 can act as a functional probiotic, alleviating diarrhea-related symptoms by inhibiting the inflammatory response and promoting the restoration of the intestinal mucosal barrier and intestinal flora.
Indexed as
Identifiers
41313536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.